AI developer Spectral AI has achieved 100% pediatric patient enrollment at burn centers for its 2024 study designed to validate the AI-driven algorithm used by the company's DeepView System for its burn indication.
The study is scheduled to be completed in the fourth quarter of 2024 and is the final clinical trial before the company seeks approval from the U.S. Food and Drug Administration (FDA) for the DeepView System for burn indication in 2025.
Spectral AI’s DeepView System uses proprietary multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points to distinguish between healthy and damaged tissue. The system can be used immediately upon a child’s arrival at the emergency department or burn center, providing noninvasive, cart-based wound assessments in support of timely clinical decision-making for burn injuries.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
